Investing.com --Jiangsu Hengrui Pharmaceuticals (HK:1276) shares rose in Hong Kong on Tuesday after Novo Nordisk entered an agreement to license the Chinese drugmaker's experimental obesity and diabetes treatment in a deal worth up to $2.6 billion. Still guessing which names to buy? Our AI rebuilds its stock picks at the start of every month. The list is beating the market by 120%. See what's on it » Hengrui shares were up 1.5% at HK$45.44, sharply outperforming the Hang Seng Index, which was down 1%. Under the agreement, Novo will gain exclusive rights to develop, manufacture and commercialize HRS-1596 globally, excluding mainland China, Hong Kong, Macao and Taiwan. Should you buy NVIDIA right now?
Wir zeigen den wichtigsten Punkt oeffentlich. Erstellen Sie ein kostenloses Konto, um den vollstaendigen Artikel zu lesen, ihn zu speichern, zu diskutieren und mit Markt- und OSINT-Kontext zu verbinden.